KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Other Accumulated Expenses data on record, last reported at $8.9 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 10.27% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $8.9 million, down 10.27%, while the annual FY2024 figure was $10.4 million, 94.9% up from the prior year.
  • Other Accumulated Expenses reached $8.9 million in Q3 2025 per RIGL's latest filing, up from $8.6 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $17.6 million in Q3 2022 and bottomed at $1.0 million in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $9.3 million, with a median of $8.9 million recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 82.15% in 2024, then soared 641.97% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $13.5 million in 2021, then plummeted by 51.98% to $6.5 million in 2022, then dropped by 17.75% to $5.3 million in 2023, then surged by 94.9% to $10.4 million in 2024, then dropped by 13.98% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $8.9 million in Q3 2025, $8.6 million in Q2 2025, and $7.4 million in Q1 2025.